NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Opus Genetics, Inc. (IRD) Stock Analysis

Opus Genetics, Inc. (IRD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IRD

$4.12

+$0.11 (+2.62%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IRD with… →

IRD Key Statistics

As of Oct 21, 2026
Trading
Open
$4.03
Previous Close
$4.01
Day's Range
4.00–4.22
52-Week Range
1.70–7.07
Volume
1.35M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.62
Valuation
Market Cap
$342.35M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
34.74
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.27
Financials (FY)
Revenue (FY)
$14.20M+29.15%
Net Income (FY)
−$49.59M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
83.20M
1-Year Return
+104.73%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
2.48M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IRD closed at $4.12, +104.73% over 1 year.

Opus Genetics, Inc. (IRD) has a market capitalization of $342.35M.

In fiscal 2025, IRD reported revenue of $14.20M.

IRD Stock Return by Calendar Year

Opus Genetics, Inc. (IRD) 10-year return: what $10,000 became

1 year
$10,000 $20,473
+104.73%
5 years
$10,000 $9,548
−4.52%
10 years
$10,000 $504
−94.96%

If you had invested $10,000 in Opus Genetics, Inc. (IRD) 10 years ago, at the close on October 21, 2016, it would have been worth $504 at the close on October 21, 2026: −94.96% in total, −25.82% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+104.73%
2025+68.91%
2024−60.47%
2023−14.73%
2022−5.36%
2021−42.53%
2020−15.05%
2019−82.89%
2018−53.96%
2017+44.29%
2016 (partial year)−48.15%

As of October 21, 2026.

IRD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.20M−$49.59M−349.3%
2024$10.99M−$57.53M−523.4%
2023$19.05M−$9.99M−52.4%
2022$39.85M$17.89M44.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.20M—−$38.60M−$49.59M−349.3%
2024$10.99M—−$34.07M−$57.53M−523.4%
2023$19.05M—−$10.56M−$9.99M−52.4%
2022$39.85M—$18.23M$17.89M44.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IRD Valuation vs Biotechnology Median

Median of 608 stocks
MetricIRDBiotechnology medianvs median
P/S ratio34.7413.30161% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Opus Genetics, Inc. (IRD) carries a market capitalisation of $342.35M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 27.

Over the past 52 weeks the price has ranged from $1.70 to $7.07. The most recent close on file for IRD is $4.12, dated October 21, 2026. That is +$0.11 (+2.62%) against the previous close. The latest close sits 142.06% above that 52-week low.

Financial Health

In fiscal 2025, Opus Genetics, Inc. reported revenue of $14.20M. Against the prior fiscal year total of $10.99M, that is a change of +29.15%. The same year closed with a net loss of $49.59M. Trailing earnings per share are −1.27.

Across the 4 fiscal years on file, revenue moves from $39.85M in 2022 to $14.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 34.74. On price-to-sales that is 161.2% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.62. Daily returns over the trailing 10 years annualize to a volatility of 86.05%. The trailing one-year total return is +104.73%. Measured over 10 years, that is −25.82% a year compounded.

Growth & Income

No dividend is on file for IRD.

The strongest complete calendar year on file is 2025 at +68.91%; the weakest is 2019 at −82.89%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +104.73%.

Peer Comparison

Opus Genetics, Inc. (IRD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Opus Genetics, Inc. IRD $342.35M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Opus Genetics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Opus Genetics, Inc.

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Visit website →